Corvus Pharmaceuticals Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. ( CRVS ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President, CEO & Chairman of the Board Conference Call Participants Zack Kubow - Real Chemistry, Inc. Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jordan Becker - Barclays Bank PLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Cha Cha Yang - Jefferies LLC, Research Division Presentation Operator Good afternoon, everyone.
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts
Company's soquelitinib shows promising phase 1 results in moderate-to-severe atopic dermatitis, with key phase 1 and phase 2 catalysts expected before the end of 2025. The drug's versatility targets both cancer and autoimmune disorders, expanding its market potential beyond oncology into other large market indications. Financial runway is limited to Q4 2026, with potential dilution risk if additional funds are raised after upcoming clinical catalysts.
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard A. Miller - Co-Founder, President, CEO & Chairman of the Board Conference Call Participants Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Zack Kubow - Real Chemistry, Inc. Operator Good afternoon, everyone.
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders.
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corvus Pharmaceuticals: The Market Likes The Story
Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked of a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus or is some profit taking on the horizon?
